Herpes simplex virus type 1 (HSV-1) corneal infection leads to establishment of a latent infection in the sensory and autonomic ganglia. HSV-1 reactivates at intervals and causes recurrent corneal infection. Repeated inflammation in the corneal stroma can lead to herpetic stromal keratitis (HSK), an immune inflammatory process that results in blindness. For optimal activation, T cells require costimulation in addition to antigen receptor signals. Constitutive receptors such as CD28 are known to provide costimulation to naive T cells. We have also shown that 4-1BB, an inducible receptor, provides costimulation to activated and memory T cells. However, whether costimulatory receptors play a role in acute, latent, and recurrent HSV-1 infection, and in HSK, is not known. It is also not known whether induction of T-cell energy by blocking costimulation can prevent HSK. Our goals are to determine the role of T-cell costimulatory molecules in herpes infection, to identify factors involved in the pathogenesis of HSK, and to investigate the therapeutic potential of blocking costimulation in HSK.
Three specific aims are proposed: 1] Test the hypothesis that the costimulatory receptors, 4-1BB and CD28, are involved in modulating acute HSV-1 infection, latency, and recurrence using 4-1BB- and/or CD28-deficient mice. 2] Determine the roles of the costimulatory receptors 4-1BB and CD28 in the pathogenesis of HSK. 3] Test the hypothesis that blocking costimulation is effective in preventing HSK. This approach (inhibition of costimulation) should be both specific and nontoxic, compared to the use of immunosuppressive drugs. These studies will aid in understanding the immunological mechanisms involved in the blinding eye condition, HSK, and allow development of strategies for the treatment of this and other ocular inflammatory diseases.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
1R01EY013325-01A1
Application #
6434739
Study Section
Visual Sciences A Study Section (VISA)
Program Officer
Shen, Grace L
Project Start
2002-04-01
Project End
2006-03-31
Budget Start
2002-04-01
Budget End
2003-03-31
Support Year
1
Fiscal Year
2002
Total Cost
$315,415
Indirect Cost
Name
Louisiana State University Hsc New Orleans
Department
Ophthalmology
Type
Schools of Medicine
DUNS #
782627814
City
New Orleans
State
LA
Country
United States
Zip Code
70112
Vinay, Dass S; Kim, Chang H; Chang, Kyung H et al. (2010) PDCA expression by B lymphocytes reveals important functional attributes. J Immunol 184:807-15
Kim, Young H; Choi, Beom K; Oh, Ho S et al. (2009) Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy. Mol Cancer Ther 8:469-78
Choi, Beom K; Kim, Young H; Kwon, Patrick M et al. (2009) 4-1BB functions as a survival factor in dendritic cells. J Immunol 182:4107-15
Kim, Young H; Choi, Beom K; Kang, Woo J et al. (2009) IFN-gamma-indoleamine-2,3 dioxygenase acts as a major suppressive factor in 4-1BB-mediated immune suppression in vivo. J Leukoc Biol 85:817-25
Vinay, Dass S; Kim, Chang H; Choi, Beom K et al. (2009) Origins and functional basis of regulatory CD11c+CD8+ T cells. Eur J Immunol 39:1552-63
Vinay, Dass S; Kwon, Byoung S (2009) TNF superfamily: costimulation and clinical applications. Cell Biol Int 33:453-65
Kim, Young H; Choi, Beom K; Kim, Kwang H et al. (2008) Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity. Cancer Res 68:7264-9
Lee, Sun Kyoung; Choi, Beom Kyu; Kang, Woo Jin et al. (2008) MCP-1 derived from stromal keratocyte induces corneal infiltration of CD4+ T cells in herpetic stromal keratitis. Mol Cells 26:67-73
Lee, Seung-Woo; Park, Yunji; So, Takanori et al. (2008) Identification of regulatory functions for 4-1BB and 4-1BBL in myelopoiesis and the development of dendritic cells. Nat Immunol 9:917-26
Rudolf, Despina; Silberzahn, Tobias; Walter, Steffen et al. (2008) Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells. Cancer Immunol Immunother 57:175-83

Showing the most recent 10 out of 38 publications